Carvalho, Maria Fernanda C. [UNESP]Viero, Rosa Marlene [UNESP]Soares, Vitor A.2014-05-272014-05-271999-04-06Renal Failure, v. 21, n. 2, p. 147-154, 1999.0886-022Xhttp://hdl.handle.net/11449/65759The role of superoxide in adriamycin-induced nephropathy (single dose; i.v. 3 mg/kg) has been studied by blocking superoxide synthesis through the administration of allopurinol (500 mg/L in drinking water). In Experiment I (EI), allopurinol administration was started 3 days prior to nephropathy induction and continued until day 14. In Experiment II (EII) allopurinol administration was started 2 weeks after nephropathy induction and was maintained until the end of the experiment (26 weeks). Affected glomeruli frequency and tubulointerstitial lesion index (TILI) were determined at Weeks 2 and 4 (EI) and Week 26 (EII). In EI, and 24 h mean proteinuria in the nephrotic control group (NCG-I) differed from that of the treated nephrotic group (TNG-I) at Week 1 (TNG = 33.3 ± 6.39 mg/24 h; NCG = 59.8 ± 6.3 mg/24 h; p < 0.05) and 2 (NCG-I = 80.0 ± 17.5 mg/24h; TNG-I = 49.1 ± 8.4 mg/24 h; p < 0.05). No glomerular alterations were observed and TILI medians were not different in both nephrotic groups at week 2 (NCG-I = 1+: TNG = 1+) and 4 (NCG = 4+; TNG = 4+). In EII, NCG-II and TNG-II presented different 24 h proteinuria values only at Week 6, (136.91 ± 22.23 mg/24 h ad 72.66 ± 10.72 mg/24 h, respectively; p < 0.05). Between nephrotic groups, there was no statistical difference in the median of affected glomeruli (CNG-II = 56%; TNG-II = 48% and TILI (NCG-II = 8+; TNG-II = 9+). Thus, allopurinol was associated with a transient reduction in proteinuria and it did not alter the progression of the nephropathy.147-154engAdriamycin nephropathyAllopurinolGlomerulosclerosisProteinuriaSuperoxideallopurinoldoxorubicinfree radicalsuperoxideanimal modelcontrolled studydrug effectdrug induced diseaseelectron microscopyglomerulosclerosisintravenous drug administrationkidney biopsykidney diseasenephrotoxicitypriority journalproteinuriapurine metabolismAntineoplastic AgentsBiopsyDisease Models, AnimalDisease ProgressionDoxorubicinFollow-Up StudiesFree Radical ScavengersGlomerulosclerosis, Focal SegmentalKidney GlomerulusKidney TubulesNephritis, InterstitialRandom AllocationRats, WistarArtigo10.3109/08860229909066979WOS:000079149000003Acesso restrito2-s2.0-00330035201453564171333848